October 23, 2020
The election and future of the country is at stake before and on November 3rd
Pre-open indications: 3 BUYs and 4 SELLs
What I provide is an “intelligence daily” to ensure that shareholders are kept apprised based on a 24-hour surveillance of “our” universe, the RegMed/cell and gene therapy sector and its surrounding markets
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! My gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times
October 23, 2020
About whom and what defines “tail-risk” going forward
Pre-open indication results: 6 HITs and 1 MISS
The week in review … the numbers speak!
An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector. I say today what others won't, so you can do what others can't.
Subscription is coming, my gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!
September 15, 2020
A scorecard of 1 restatement and 1 acquisition of 35 covered companies The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"
August 12, 2020
16,675 million shares were offered which included an additional 2,175 million underwiter option Goldman Sachs & Co. LLC, Cowen and Company, LLC, SVB Leerink LLC and Piper Sandler & Co. are acting as joint book-running managers for the proposed offering. ADVM is DOWN -$0.16 to $13.55 at closing
July 8, 2020
BLFS' underwriters' option included an additional 776,250 shares The gross proceeds from the offering to BLFS, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $86 million.
October 22, 2020
RegMed Investors’ (RMi) pre-open: volatility “ain’t” leaving